SCHEMBL7907523

SCHEMBL7907523

CNC(=S)NCC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
PTPRC P08575 2/20 0.36
CA12 O43570 3/20 0.35
CA2 P00918 3/20 0.35
CA14 Q9ULX7 1/20 0.35
CA1 P00915 2/20 0.35
CA9 Q16790 2/20 0.35
GAA P10253 3/20 0.35
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DGAT1 O75907 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CYP2D6 P10635 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TET2 Q6N021 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365853 0.79 PTPRC (0.38) PTPRCCA12CA2CA14GAA
SCHEMBL15340973 0.78 MAOA (0.41) ALDH1A1PTPRCCA12CA2CA14
SCHEMBL6610608 0.76 MEN1 (0.41) PTPRCCA12CA2CA14GAA
SCHEMBL410255 0.76 CA2 (0.40) PTPRCCA12CA2CA14CA1
SCHEMBL14056719 0.76 PTPRC (0.36) PTPRCCA12CA2CA14GAA
Hydrochloric Acid SCHEMBL219630 0.74 CA2 (0.39) PTPRCCA12CA2CA14CA1
SCHEMBL6937980 0.74 MEN1 (0.40) PTPRCCA12CA2CA14GAA
SCHEMBL7660758 0.74 PTPRC (0.40) LMNAPTPRCCA12CA2CA14
Hydrochloric Acid SCHEMBL31480795 0.74 CA2 (0.39) PTPRCCA12CA2CA14CA1
SCHEMBL125503 0.74 TDP1 (0.52) ALDH1A1CA12CA2CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6288093-B1 COMPOUNDS SUCH AS (6-CHLORO-3-METHYL-3,8-DIHYDROINDENO (1,2-D)THIAZOL-2-YLIDENE)METHYLAMINE HYDROBROMIDE USED AS ANORECTICS AND ANTIDIABETICS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-09-11 US disclosed
US-6288094-B2 COMPOUNDS SUCH AS (6-CHLORO-3-METHYL-3,8-DIHYDROINDENO (1,2-D)THIAZOL-2-YLIDENE)METHYLAMINE HYDROBROMIDE USED AS ANORECTICS AND ANTIDIABETICS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-09-11 US disclosed
US-20010011096-A1 Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-08-02 US disclosed
US-6207689-B1 AS ANORECTICS AND IN THE TREATMENT OR PROPHYLAXIS OF TYPE II DIABETES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010011096-A1 Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments SLC5A2, OTC, GOT2 ALDH1A1 289/4885LMNA 2551/4885PTPRC 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.